
    
      This study is a double-blind, randomized, placebo-controlled study that will examine the
      acute and chronic renal effects of empagliflozin in healthy volunteers.

      A total of 45 healthy volunteers will be included in the study: 15 normal weight, 15
      overweight (BMI: 25-30kg/m2) and 15 obese (BMI>30kg/m2) non diabetic subjects (as determined
      after an oral glucose tolerance test).

      Empagliflozin 10mg vs placebo will be administered in a blinded fashion qd. The acute and
      chronic renal response to empagliflozin will be assessed.
    
  